abstract |
Provided are a novel polyvalent human papillomavirus (HPV) DNA vaccine, a fusion protein used therein, and a polynucleotide encoding the fusion protein, and more specifically, a polyvalent HPV DNA vaccine composition including polynucleotides, which encode early protein antigen 6 (E6) of types 6, 11, 16, 18, 39, 45, and 56 HPV or immunogenic fragments thereof; and early protein antigen 7 (E7) of types 6, 11, 16, 18, 39, 45, and 56 human papillomavirus (HPV) or immunogenic fragments thereof, respectively. |